Speaker

Dr. Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at the Harvard Medical School since 2001. He was the founding Director of the Harvard Partners Center for Genetics and Genomics. He obtained his PhD from the University of illinois, conducted post-doctoral studies at Yale University and held faculty positions at Princeton University. Before moving to Harvard, Dr. Kucherlapati was the University Chairman and the Lola and Saul Kramer Professor and chair of the Department of Molecular Genetics at the Albert Einstein College of Medicine in New York. Dr. Kucherlapati was a part of the Human Genome Project and the Cancer Genome Atlas project. He is a member of the National Academy of Medicine, USA.

Mr. Takayuki Kusanagi earned his MBA from Harvard Business School in 1985 and a BA in Economics from Keio University in 1981. Mr. Kusanagi is currently the CEO of Cuorips, Inc, where he has led the company since 2020 and successfully guided its IPO in 2023. Before becoming CEO, he joined as an Advisor and board member to prepare the company for its IPO.
Mr. Kusanagi has over 40 years of experience in finance and investment management. He previously served as General Manager at Entrust, Inc, where he designed tax-saving schemes, created family office and advised on private investments. Earlier, he was CIO of YMR, overseeing Japanese equities, and General Manager of the Investment Banking Products Department at Mizuho Securities, leading securitization and M&A. He also held fund manager role at Daiichi IBJ Asset Management and spent nearly 20 years at the Industrial Bank of Japan (now Mizuho Bank) in different functions spanning international banking, credit analyst, investment management, derivatives trading, and securities analyst.

Ir Tommy Lam serves as a Senior Engineer of the Medical Device Division in the Department of Health of the HKSAR Government.  He is mainly responsible for the implementation of the Medical Device Administrative Control System and management of relevant IT services, with a view to facilitating the development of a long-term statutory regulatory framework for medical devices in Hong Kong.  Drawing on a background in electronics and biomedical engineering, Ir Lam previously worked in various divisions at the Electrical and Mechanical Services Department, including hospital engineering, innovation, and technology and media relations.  His work there focused on adopting artificial intelligence and digitalization in engineering services, an area of knowledge he now applies to the medical device regulatory field.

Dr. Lang Na is a Chief Physician and Deputy Director of the Disease Prevention Center at Xiyuan Hospital, China Academy of Chinese Medical Sciences (CACMS). A Ph.D. graduate from CACMS, she is a recognized National Backbone Talent in TCM inheritance. Dr. Lang also serves as a Doctoral Supervisor at CACMS and a Master’s Supervisor at Beijing University of Chinese Medicine. She holds key roles in several prestigious academic committees, including the Dermatology Committee of the Beijing Association of Chinese Medicine. An active researcher, she has led over 10 national and provincial projects and published more than 20 papers as first or corresponding author. Her outstanding research contributions have been honored with the Third Prize of the Chinese Association of Integrative Medicine Science and Technology Award.

Professor Chak-sing Lau is currently Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at The University of Hong Kong. He is meanwhile Chair and Daniel CK Yu Professor in Rheumatology and Clinical Immunology of the University’s Li Ka Shing Faculty of Medicine (HKUMed).

He presided over the Hong Kong Academy of Medicine (2016 – 2020), a statutory body for medical and dental specialist training in Hong Kong which is also a key advisory body to the HKSAR Government on health-related policies. Today, he sits on numerous strategic committees/ working groups of the Health Bureau, Hospital Authority and Department of Health. He is also a member of the Research Council under the Health Bureau.

Professor Lau is known as a pioneer for establishing and advancing rheumatology in Hong Kong, Asia and beyond. In 2022, he was selected as an Honorary Member of the European Alliance of Associations for Rheumatology (EULAR), and elected as a Member of Academia Europaea in 2023, and conferred the degree of Doctor of Science honoris causa by the University of Glasgow in 2024. He is Honorary Fellow of the American College of Physicians; the Academy of Medicine, Singapore; the Singapore College of Physicians; the Royal College of Physicians of Thailand; the Academy of Medicine of Malaysia; the Royal College of Physicians of Ireland; and the Hong Kong Academy of Medicine. 

Hsiang-Ying Lee is a Principal Investigator at the School of Life Sciences, Peking University, and the Peking-Tsinghua Center for Life Sciences. Using red blood cell development as a model, her research integrates multi-omics approaches to elucidate the chromatin regulatory mechanisms underlying hematopoiesis, investigate the pathological processes of hematopoietic development and aplasia, and identify potential diagnostic and therapeutic targets. Her work, as first or corresponding author, has been published in journals including Nature, Cell, Nature Structural & Molecular Biology, and Molecular Cell. She has been awarded the National High-Level Overseas Talent Program and has received the Class A (formerly Distinguished Young Scholar) grant from the National Natural Science Foundation of China.

Prof Simon Lee’s research interests interest lies in the discovery of drug-like agents from natural products including small molecules and biologics for use in various therapeutic areas, including brain disorder and neurodegenerative diseases. His dedication to education and research in the fields of omics, pharmacology and toxicology has led to over 360 scholarly articles, including Nature, Nature Genetics, Nature Communications (4×) and Science Advances, and over 20 granted patents. Simon is in Stanford university’s list of top 2% of most-cited scientists in Pharmaceutical Science and Biology (with h-index: 65 from Scopus). His dedication to education and research in the fields of pharmacology and toxicology has led to over 300 scholarly articles, including Nature Communications (4×), and over ten granted patents. He has received over 30 grants (exceeding 80 million Hong Kong dollars),. Prof Simon Lee has extensive collaboration experience with pharmaceutical and biotechnology industries. He has founded AIM Pharmaceutical International Limited (AIM Pharma), specializes in developing innovative nutraceuticals and therapeutic drugs for neurodegenerative diseases, which has been selected for RAISe+ scheme in 2025.

Dr. Shawn Lee founded Chinese Peptides Company in 2001, leading an international-standard team to achieve significant breakthroughs in peptide R&D and industrialization. In 1989, Dr. Lee co-founded American Peptide Company in Silicon Valley, where he served as Chief Operating Officer, overseeing all aspects of the company’s operations. In 2005, he founded CPC Scientific Inc. in Silicon Valley, and has served as its CEO ever since.

Dr. Lee is an outstanding peptide expert with over 30 years of experience, having propelled the clinical development and industrialization of over a hundred peptide drugs. He possesses extensive experience in complex peptide modification and synthesis, international regulations, peptide drug industrialization, and the creation of novel peptide drugs. Dr. Lee previously served as Vice Chairman and Director of Xinbang Pharmaceutical. (002390) from 2015 to 2020, and was a co-founder of Lake Ventures from 2017 to 2021. He is also a visiting professor at the University of the Pacific School of Pharmacy in the United States. In 2024, Dr. Li was appointed President of the CPC Innovation Technology Research Institute (CITRI).

Dr. Lee received his Ph.D. in Science from the Chinese Academy of Sciences in 1989, followed by a postdoctoral fellowship at the University of California, Berkeley. He also holds an MBA from IMD business school of Switzerland and an EMBA from Cheung Kong Graduate School of Business, and was recognized as a Centennial PUMC-First Scholar in Medicine and Health Industry.

Dr. Wayne Lee earned his PhD in Pharmacology from The Chinese University of Hong Kong (CUHK) in 2009, followed by postdoctoral training in Orthopaedics and Traumatology at CUHK, specializing in cell therapy. With over 127 publications in peer-reviewed international journals and a Scopus H-index of 36, his research is supported by prestigious grants, including RGC, HMRF, ITF, InnoHK, and ASBMR. Dr. Lee serves on the Youth Committee of the Journal of Orthopaedic Translation and is Co-Director of the CUHK-Nanjing University Joint Scoliosis Research Society. From 2022 to 2025, he was the Site Authorized Person at the ATP GMP Center, Hong Kong Institute of Biotechnology, securing the first local institution-led ATP manufacturing license and releasing several CAR-T products for clinical trials. His work focuses on GMP-compliant advanced cell therapies and novel drug interventions for musculoskeletal disorders. In 2024, Dr. Lee co-founded Trilateral Biopharmaceutical, a spin-off from the InnoHK Center for Neuromusculoskeletal Restorative Medicine, driving innovation in regenerative medicine to improve patient outcomes.

Co-founder, Silver Dart Capital Partner (Healthcare Investments), Value Partners Group

Dr. Chuen Yan Leung is currently Partner (Healthcare Investments) at Value Partners Group, one of Asia’s largest independent asset management firms offering world-class investment services and products for institutional and individual clients globally. He has 14 years of experience in the healthcare ecosystem from R&D, biotechnology start-ups, venture capital, and private equity. Previously Dr. Leung was a co-founder of Silver Dart Capital, a boutique healthcare private equity firm and a private equity vice president at EQT Group, a Swedish global investment organization with EUR 210bn assets under management as of 2023. He has previously held roles such as Vice President at Aeneas Capital and Lead Scientist at Procella Therapeutics. Dr. Leung is currently the Vice President of the Hong Kong Biotechnology Organization, and a member of the Shanghai Pudong Chinese People’s Political Consultative Conference. Dr. Leung received his PhD in Stem Cell Biology from the University of Cambridge, and BSc in Biochemistry from Imperial College London.